Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Recursion (Nasdaq: RXRX) has published significant findings in Nature Genetics, revealing a proximity bias in CRISPR-Cas9 gene editing. This bias, identified through Recursion's vast biological dataset, indicates large-scale structural changes in the genome caused by CRISPR-Cas9. The study, titled “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing,” presents a debiasing algorithm to correct this issue.
Recursion's approach uses proprietary AI to analyze high-dimensional measurements from edited cells, creating detailed biological maps. These findings have wide implications for understanding disease mechanisms and developing new therapeutic approaches. The company also confirmed the presence of this bias in public data sets and proposed solutions to improve data quality.
Imran Haque, SVP of AI and Digital Sciences at Recursion, emphasized the importance of these findings for the scientific community and the ongoing efforts to enhance drug discovery and gene editing.
- Recursion's study identifies a previously unknown proximity bias in CRISPR-Cas9 gene editing, showing the company's capability in cutting-edge research.
- The development of a debiasing algorithm by Recursion demonstrates innovation and problem-solving in gene editing.
- Recursion's use of proprietary AI for high-dimensional cell measurements positions the company as a leader in integrating technology with biology.
- The findings could lead to significant advancements in understanding and treating diseases, potentially enhancing Recursion's drug discovery pipeline.
- Confirmation of the proximity bias in public datasets indicates Recursion's research impact extends beyond internal projects, benefiting the broader scientific community.
- Identification of a proximity bias in CRISPR-Cas9 could imply limitations in existing gene editing techniques, possibly affecting the perceived reliability of Recursion's methodologies.
- The need for a debiasing algorithm suggests current CRISPR-Cas9 applications may have inherent flaws, potentially raising concerns among investors about past data accuracy.
- Large-scale structural changes in the genome due to CRISPR-Cas9 editing might necessitate re-evaluation of existing research, causing delays and increased costs.
Insights
Recursion's revelation of a proximity bias in CRISPR-Cas9 gene editing presents both opportunities and risks. On the positive side, the identification of this bias and the development of a debiasing algorithm could significantly enhance the accuracy of CRISPR applications. This advancement positions Recursion as a leader in the techbio space, potentially attracting more partnerships and funding. However, the news also highlights a fundamental limitation in a widely-used technology, which could lead to market volatility. Investors should monitor how Recursion leverages these findings into commercial success and how the market reacts to potential uncertainties surrounding CRISPR technology.
The discovery of chromosomal truncations caused by CRISPR-Cas9 underscores the importance of precision in gene-editing technologies. For researchers, these findings offer critical insights into the potential side effects of CRISPR, paving the way for more refined gene-editing tools. Recursion's ability to detect and mitigate these biases using their proprietary datasets and AI models is a significant advancement. This could lead to safer and more effective therapeutic approaches, enhancing the company's reputation within the scientific community and potentially accelerating drug discovery.
Recursion's use of AI to identify and correct proximity bias in CRISPR-Cas9 is a remarkable feat. This demonstrates the power of integrating large-scale phenotypic data with advanced AI models to uncover hidden biases and improve the reliability of genetic tools. By refining CRISPR-based techniques, Recursion not only enhances its own research capabilities but also sets a new standard in the techbio industry. This development may prompt other companies to adopt similar AI-driven approaches, potentially revolutionizing the field of gene editing.
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm.
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches.
This proximity bias, discoverable through Recursion’s proprietary biological dataset, could have many downstream impacts on the community’s ability to make meaningful progress in our understanding and treatment of disease within both large scale datasets and small gene-specific work.
CRISPR-Cas9 is a revolutionary technology that can be used as “molecular scissors” to edit the human genome. Upon investigation of the massive datasets within the Recursion OS, Recursion identified large-scale structural changes to the genome – chromosomal truncations – caused by CRISPR-Cas9 editing. The Recursion team subsequently confirmed the widespread presence of this effect in several widely-used public data resources, and, using proprietary datasets and its full stack techbio platform, developed and demonstrated a correction method to analytically mitigate this proximity bias in CRISPR screen datasets at scale.
Recursion applies CRISPR to systematically “knockout” or delete each of >17,000 individual genes in cells as part of its phenotypic screening process. High-dimensional measurements of the edited cells, such as microscopy or scaled transcriptomics, are integrated using proprietary AI to build “maps of biology” to infer biological pathways and uncover new approaches to treating disease. This methodology is applicable across a wide swath of biology, with Recursion’s internal discovery pipeline and our external partnerships.
“Over several years, Recursion has built both unique scale and experience of working with CRISPR-Cas9. By combining the massive scale enabled by Recursion's phenomics platform with our highly sensitive AI models for image analysis, we were able to discover a subtle bias in CRISPR-Cas9 with meaningful consequences for drug discovery and gene editing. We're excited to share with the community not only these findings but also potential solutions to improve the quality of inferences from large-scale public data,” shares Imran Haque, PhD, Senior Vice President of AI and Digital Sciences.
About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Media Contact
Investor Contact
Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s leadership of the TechBio space; the impact of the discovery of proximity bias in CRISPR-Cas9 editing and potential solutions; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
FAQ
What did Recursion's study in Nature Genetics reveal?
How did Recursion address the proximity bias in CRISPR-Cas9 gene editing?
What is the significance of Recursion's findings on CRISPR-Cas9?
How does Recursion use AI in its research?
What impact could Recursion's findings have on the scientific community?
